143,927 results match your criteria Metastatic Carcinoma


Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.

PLoS One 2019 20;14(2):e0211105. Epub 2019 Feb 20.

Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea.

Objective: This study aimed to determine the prognostic factors of progression-free survival (PFS) and overall survival (OS) in non-nephrectomized patients with synchronous metastatic renal cell carcinoma (mRCC) receiving first-line vascular endothelial growth factor (VEGF)-targeted therapy or immunotherapy.

Methods: Of 70 patients, 57 (81.4%) were treated with targeted therapy, including 5 (7. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211105PLOS
February 2019

Circular RNA expression in exosomes derived from breast cancer cells and patients.

Epigenomics 2019 Feb 20. Epub 2019 Feb 20.

Center of Clinical Laboratory Science, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, PR China.

Aim: We aimed to explore the roles of circular RNAs (circRNAs) in breast cancer (BCa).

Materials & Methods: RNA was extracted from exosomes and BCa cells and analyzed using the RNA sequencing technique or microarray.

Results: Compared with controls, 1147 and 1195 circRNAs were dysregulated in exosomes from metastatic and localized BCa patients, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi-2018-0111DOI Listing
February 2019

Cetuximab and Methotrexate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Single Institution Analysis of 54 Patients.

Clin Otolaryngol 2019 Feb 19. Epub 2019 Feb 19.

Department of Hematology-Oncology and Urology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Cetuximab (CTX) and methotrexate (MTX) have both shown single-agent activity in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) but data on CTX/MTX combination is limited. We report safety and efficacy data of 54 R/M HNSCC patients treated with concurrent CTX/MTX. Median progression-free survival and overall survival were 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/coa.13316DOI Listing
February 2019

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.

Authors:
Mahtab Samimi

Am J Clin Dermatol 2019 Feb 19. Epub 2019 Feb 19.

Dermatology Department, University Hospital of Tours, Avenue de la République, 37170, Chambray-les-Tours, France.

Merkel cell carcinoma (MCC) is an aggressive skin cancer. Until 2017, patients with advanced disease were typically treated with conventional chemotherapies, with a median response duration of 3 months. Increased evidence of the role of the immune system in controlling this cancer has paved the way for immune-based therapies, with programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors at the frontline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00427-9DOI Listing
February 2019

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.

Drugs Aging 2019 Feb 20. Epub 2019 Feb 20.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Suite 2161, Salt Lake City, UT, 84112, USA.

Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age, is limited. This is further complicated by clinical trials not commonly reporting adverse events by age. Thus, recommendations on treatment of older patients with mRCC are generally extrapolated from data on younger patients enrolled in these trials, which may not be ideal as many older patients are frail, have age-related organ dysfunction, or have multiple medical co-morbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-019-00644-1DOI Listing
February 2019

The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

J Gastrointest Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Medical Oncology, Faculty of Medicine, Zagazig University Zagazig, Zagazig, Egypt.

Background: Early detection of small HCC and differentiation between HCC from AC metastatic to the liver is very essential for surgical pathologists, due to different treatment modalities. Immunohistochemistry plays a very important role in such conditions. In our study, we aimed to identify the diagnostic benefits of Arginase-1, FTCD& MOC-31 in the early detection of HCC in normal or cirrhotic liver, differentiation between HCC and metastatic ACs to the liver, and for early detection of small micro-metastases from ACs to liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-019-00211-2DOI Listing
February 2019

Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results.

Oncotarget 2019 Jan 25;10(8):847-855. Epub 2019 Jan 25.

Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.

Background: Although triplet regimen of docetaxel, cisplatin, and 5-FU (DCF) reportedly yields high response rates for metastatic squamous cell carcinoma of the esophagus (SCCE), it has severe toxicity. In our previous phase II trial, grade 3/4 toxicities of neutropenia occurred in 68.8% of the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368232PMC
January 2019

The repair using a fibular graft of cervical vertebral collapse due to renal cell carcinoma: Late results with a case report.

J Craniovertebr Junction Spine 2018 Oct-Dec;9(4):267-270

Department of Pathology, Research and Training Hospital, Recep Tayyip Erdogan University, Rize, Turkey.

The most common cause of spinal tumors is metastases, but the cervical vertebra is the least common region of spinal metastasis, and relatively, little is published about surgery in metastasis to the cervical vertebra. While spinal metastasis is most often caused by neoplasms originating from the lung, breast, and prostate, renal cell carcinoma (RCC) metastasis is very rare. A 47-year-old patient introduced here presented with severe pain spontaneously on his neck and in his arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcvjs.JCVJS_32_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364372PMC
February 2019

A case of capecitabine-induced dermatomyositis.

Indian J Pharmacol 2018 Nov-Dec;50(6):350-353

Department of Dermatology, MLN Medical College, Allahabad, Uttar Pradesh, India.

Dermatomyositis (DM) is an idiopathic, inflammatory connective tissue disorder characterized by symmetrical proximal myopathy and characteristic skin involvement. The pathogenesis of DM is widely debated; however, it is postulated to be an end result of immune-mediated cascade, triggered by multiple environmental factors in a genetically predisposed individual. In addition to underlying malignancies, many drugs have been reported to be associated with DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijp.IJP_356_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364339PMC
February 2019

Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence.

Am J Surg 2019 Mar 16;217(3):541-545. Epub 2018 Oct 16.

Spectrum Health General Surgery Residency Program, Grand Rapids, MI, USA; Michigan State University College of Human Medicine, Department of Surgery, Grand Rapids, MI, USA; Spectrum Health Medical Group, Division of Surgical Oncology, Grand Rapids, MI, USA. Electronic address:

The practice of hepatic surgery has become increasingly complex as additional therapeutic options emerge to treat both primary and metastatic tumors of the liver. Liver-directed therapy options include selective internal radiation therapy (SIRT), stereotactic body radiation therapy, chemoembolization, bland embolization, hepatic artery infusion chemotherapy (HAIC), and ablative techniques such as microwave or radiofrequency ablation. Hepatocellular carcinoma has been treated with many of these therapies for palliation of symptoms, definitive treatment, and as a bridge to transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2018.10.018DOI Listing

Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience.

Radiat Oncol 2019 Feb 19;14(1):34. Epub 2019 Feb 19.

Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Purpose: Salvage surgery of recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) results in limited local control and survival rates. As a result of recent technological progress, radiotherapy (RT) has become a valuable, potentially curative therapeutic option. Thus, we aimed to determine prognostic factors for survival outcome in order to optimize patient selection for salvage radiotherapy after failure of first-line treatment with surgery alone in this special patient cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1238-8DOI Listing
February 2019

The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.

Tumori 2019 Feb 19:300891619829571. Epub 2019 Feb 19.

2 Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Purpose:: Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when and which TKI has to be started in R/M MTC patients. This is due to 1) TKI-related toxicity burden, 2) no overall survival benefit for either TKI, and 3) progression-free survival improvement in MTC subgroups ( RETM918T and RAS mutations) treated with cabozantinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300891619829571DOI Listing
February 2019

Leukocyte⁻Cancer Cell Fusion-Genesis of a Deadly Journey.

Cells 2019 Feb 18;8(2). Epub 2019 Feb 18.

Department of Dermatology and The Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8059, USA.

According to estimates from the International Agency for Research on Cancer, by the year 2030 there will be 22 million new cancer cases and 13 million deaths per year. The main cause of cancer mortality is not the primary tumor itself but metastasis to distant organs and tissues, yet the mechanisms of this process remain poorly understood. Leukocyte⁻cancer cell fusion and hybrid formation as an initiator of metastasis was proposed more than a century ago by the German pathologist Prof. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8020170DOI Listing
February 2019

Yifei Tongluo, a Chinese Herbal Formula, Suppresses Tumor Growth and Metastasis and Exerts Immunomodulatory Effect in Lewis Lung Carcinoma Mice.

Molecules 2019 Feb 18;24(4). Epub 2019 Feb 18.

School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, Shandong, China.

This study was aimed to investigate the anti-tumor, anti-metastasis and immunomodulatory effects of Yifei Tongluo (YFTL), a Chinese herbal formula, in Lewis lung carcinoma mice and to explore the underlying mechanisms. LLC cells were inoculated subcutaneously in C57BL/6 mice to establish the Lewis lung carcinoma model. We observed that YFTL effectively inhibited tumor growth and prolonged the overall survival of tumor-bearing mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24040731DOI Listing
February 2019

Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer.

Cancers (Basel) 2019 Feb 18;11(2). Epub 2019 Feb 18.

Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío (HUVR), Universidad de Sevilla, Consejo Superior de Investigaciones Científicas, 41013 Seville, Spain.

Tumors are cellular ecosystems where different populations and subpopulations of cells coexist. Among these cells, cancer stem cells (CSCs) are considered to be the origin of the tumor mass, being involved in metastasis and in the resistance to conventional therapies. Furthermore, tumor cells have an enormous plasticity and a phenomenon of de-differentiation of mature tumor cells to CSCs may occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020235DOI Listing
February 2019

Long-term Survival of Patient with Ampulla of Vater Metastasis of Renal Cell Carcinoma.

Prague Med Rep 2018 ;119(4):165-169

Department of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Ampulla of Vater metastases from renal cell carcinoma are rare. The time between detection of the primary tumour and its metastasis may extend to years. Management should be aggressive, since the prognosis of renal cell carcinoma is unpredictable and curative surgery of metastases may extend patient survival and even lead to definite cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14712/23362936.2019.4DOI Listing
January 2018

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital-Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) - all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) - both in France; the University of Texas M.D. Anderson Cancer Center, Houston (M.T.C.); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow (B.V.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; British Columbia Cancer Agency, Vancouver (C.K.), and Lady Davis Institute and Jewish General Hospital, McGill University, Montreal (W.H.M.) - both in Canada; Osaka University Hospital, Osaka, Japan (M.U.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.L.L.); Macquarie University, Sydney (H.G.); Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna (M.S.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.); Department of Urology, University of Tübingen, Tübingen, Germany (J.B.); Pfizer, Cambridge (J.W., A.C.), and the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston (T.K.C.) - both in Massachusetts; Pfizer (M.M., A.P.) and Pfizer Italia (C.F.), Milan; Pfizer, San Diego, CA (P.B.R.); and Pfizer, Groton, CT (B.H.).

Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib.

Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816047DOI Listing
February 2019

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

Background: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.

Methods: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
February 2019

Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

Authors:
Bernard Escudier

N Engl J Med 2019 02 16. Epub 2019 Feb 16.

From the Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1900887DOI Listing
February 2019

F-FDG and F-FAMT PET-derived metabolic parameters predict outcome of oral squamous cell carcinoma.

Oral Radiol 2019 Feb 18. Epub 2019 Feb 18.

Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Objectives: L-3-[F]-Fluoro-α-methyl tyrosine (FAMT), an amino acid positron emission tomography (PET) tracer, complements [F]-fluorodeoxyglucose (FDG) in the diagnosis of malignancies. We compared the predictive ability of FAMT PET versus FDG PET regarding metastatic oral squamous cell carcinoma (OSCC) outcomes for distant metastasis, including lymph node metastasis, and identified the relevant metabolic parameters for each.

Methods: We enrolled 160 patients with OSCC who underwent PET/computed tomography using FDG and FAMT before treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11282-019-00377-2DOI Listing
February 2019

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

J Immunother Cancer 2019 Feb 18;7(1):49. Epub 2019 Feb 18.

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Background: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0522-3DOI Listing
February 2019

Safety and technical feasibility of percutaneous ablation for lymph node metastases of hepatocellular carcinoma.

Int J Hyperthermia 2019 Feb 19:1-9. Epub 2019 Feb 19.

a Center of Interventional Oncology and Liver Diseases , Beijing You'an Hospital, Capital Medical University , Beijing , China.

Purpose: This study aimed to assess the safety and technical feasibility of percutaneous ablation therapy for lymph node (LN) metastases of hepatocellular carcinoma (HCC).

Material And Methods: A total of 31 consecutive HCC patients with LN metastases who were treated with ablation were included in this retrospective study. Percutaneous ablation was performed under local anesthesia and computed tomography-guidance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02656736.2018.1542510DOI Listing
February 2019

Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur.

Int J Radiat Oncol Biol Phys 2019 Feb 15. Epub 2019 Feb 15.

Radiation Oncology Department, CHUV Lausanne, Switzerland.

Purpose: The "xxx" phase II trial (NCTxxx) assessed the efficacy of pravastatin as anti-fibrotic agent in patients with established cutaneous and subcutaneous radiation-induced fibrosis (RIF) after head and neck squamous cell carcinoma (HNSCC) radiotherapy and/or radio-chemotherapy.

Methods And Materials: The main inclusion criteria were: patients with HNSCC in remission, with grade ≥2 cutaneous and subcutaneous neck RIF (NCI-CTCAE v4.0); no current treatment with statins or fibrates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.02.024DOI Listing
February 2019

Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.

Cancer Sci 2019 Feb 18. Epub 2019 Feb 18.

Gastric Surgery Division, National Cancer Center Hospital, Tokyo.

Neural invasion is one of the malignant features contributing to locally advanced and/or metastatic disease progression in patients with pancreatic ductal adenocarcinoma (PDAC). Few studies exist about the distribution and state of nerve fibers in PDAC tissue and about their clinicopathological impacts. The aim of this study was to investigate the clinicopathological characteristics and prognostic value of intrapancreatic neural alterations in patients with PDAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13975DOI Listing
February 2019

A case of metastatic brain tumor mimicking an expanding thalamic hematoma.

Surg Neurol Int 2019 15;10. Epub 2019 Jan 15.

Department of Pathology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.

Background: Brain tumor are a major etiology of secondary intracranial hemorrhage (ICH) because ICH in patients with cancer often occurs from an intratumoral hemorrhage. However, it is sometimes difficult to detect a tumor when it is tiny and buried, especially during initial examination.

Case Description: A 65-year-old woman who was diagnosed with pulmonary small cell carcinoma 6 months previously developed sudden-onset consciousness disturbance and left hemiparesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sni.sni_318_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357533PMC
January 2019

Resistances to tyrosine kinase inhibitors in lung cancer-how to routinely track them in a molecular pathology laboratory?

J Thorac Dis 2019 Jan;11(Suppl 1):S65-S70

Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, CHU Nice, FHU OncoAge, Université Côte d'Azur, Nice, France.

Patients with advanced or metastatic forms of lung cancer with an activating mutation in () are given tyrosine kinase inhibitors (TKIs) targeted therapies that are more efficient than chemotherapy. These patients are excluded from first-line immunotherapy. After a phase of regression these tumors develop systematically resistance requiring a rapid change in therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.76DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353744PMC
January 2019

The importance of appropriate reporting and investigation of incidental findings on computed tomography attenuation correction images during myocardial perfusion scintigraphy.

World J Nucl Med 2019 Jan-Mar;18(1):74-76

Department of Medical Imaging, The Prince Charles Hospital, Brisbane, Australia.

We present a case of lung cancer incidentally detected as a pulmonary nodule on computed tomography attenuation correction (CTAC) images during myocardial perfusion scintigraphy (MPS). Unfortunately, the incidental lesion was not fully investigated following MPS report and had developed into metastatic lung carcinoma when diagnosed over 1 year later, with failure of subsequent emergent chemotherapy. The disease appeared to be localized when initially detected during MPS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/wjnm.WJNM_19_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357710PMC
February 2019

DIAGNOSIS AND MANAGEMENT OF PAGET'S DISEASE OF BONE - SERIES OF 8 CASES.

Acta Ortop Bras 2019 Jan-Feb;27(1):31-32

Universidade Estadual de São Paulo Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil.

Paget's disease of bone is a chronic condition characterized by focal abnormalities of absorption and formation of bone, and it may lead to anatomical deformities, pain, fractures, and malignant transformation. It is common in the UK, Australia, New Zealand, and North America and has a strong hereditary component, affecting first- to third-degree relatives. The etiology remains unclear and treatment is based on control of the disease with bisphosphonates, with the aim of relieving symptoms and correcting laboratory abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1413-785220192701161107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362702PMC
February 2019

Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma.

Cancer Manag Res 2019 23;11:981-996. Epub 2019 Jan 23.

Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,

Purpose: Transcatheter arterial embolization or transcatheter arterial chemoembolization has become a critical therapy for unresectable hepatocarcinoma. Although hypoxia caused by embolization can induce apoptosis and necrosis of the majority of tumor cells, a small proportion of cells can survive with hypoxia and chemotherapy resistance. HIF-1α induced by hypoxia is the key factor rendering surviving tumor cells invasive and metastatic properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S189208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350642PMC
January 2019

Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis.

Onco Targets Ther 2019 1;12:1007-1020. Epub 2019 Feb 1.

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China,

Background: The expression and function of the Receptor for Activated C Kinase 1 (RACK1) in cancer growth and metastasis are confused in different cancers, especially in pancreatic ductal adenocarcinoma (PDAC).

Methods: One-hundred and eighty-two PDAC tissue specimens (95 males and 87 females) including pancreatic cancer tissue and para-carcinoma tissue were collected for analysis between 2005 to 2012. Blood phenotypic parameters using cell count and capillary electrophoresis were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S176101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362924PMC
February 2019
1.342 Impact Factor

HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.

Radiother Oncol 2019 Feb 17;131:27-34. Epub 2018 Dec 17.

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

Purpose: The prognosis of unresectable stage III non-small cell lung cancer (NSCLC) was poor even after concurrent chemoradiotherapy. There remains a great need to develop novel therapeutic agents in combination with CCRT to improve outcomes. This prospective study sought to evaluate the efficacy and toxicities of the addition of endostar, an anti-angiogenesis agent, to concurrent etoposide, cisplatin (EP) and radiotherapy for treatment of patients with NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2018.10.032DOI Listing
February 2019

Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.

Radiother Oncol 2019 Feb 31;131:135-144. Epub 2018 Dec 31.

Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Background And Purpose: Stereotactic body radiotherapy (SBRT) is an emerging ablative modality for hepatocellular carcinoma (HCC). This study aimed to synthesize available evidence to evaluate the clinical feasibility and efficacy of SBRT for HCC.

Materials And Methods: A systematic search was performed of the PubMed, Medline, Embase, and Cochrane Library databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2018.12.005DOI Listing
February 2019

Small Cell Lung Cancer with Pituitary Metastasis Presenting as Secondary Adrenal Insufficiency: A Case Report and Literature Review.

Am J Case Rep 2019 Feb 17;20:207-211. Epub 2019 Feb 17.

Department of Endocrinology, University of California San Francisco, San Francisco, CA, USA.

BACKGROUND Pituitary gland metastasis is rarely the initial presentation of metastatic cancer. Most cases of pituitary gland metastasis are asymptomatic with diabetes insipidus being the most common symptomatic presentation. It can rarely present with symptoms of hormone underproduction such as secondary adrenal insufficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.913388DOI Listing
February 2019
1 Read

Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer.

J Proteomics 2019 Feb 14. Epub 2019 Feb 14.

Genetics Department, Federal University of Parana, Curitiba, Brazil. Electronic address:

Proteins play an essential role in the biological processes associated with cancer. Their altered expression levels can deregulate critical cellular pathways and interactive networks. In this study, the mass spectrometry-based label-free quantification followed by functional annotation was performed to investigate the most significant deregulated proteins among tissues of primary breast tumor (PT) and axillary metastatic lymph node (LN) and corresponding non-tumor tissues contralateral (NCT) and adjacent (ANT) from patients diagnosed with invasive ductal carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2019.02.007DOI Listing
February 2019
1 Read

TOX3 Inhibits Cancer Cell Migration and Invasion via Transcriptional Regulation of SNAI1 and SNAI2 in Clear Cell Renal Cell Carcinoma.

Cancer Lett 2019 Feb 14. Epub 2019 Feb 14.

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, PR China. Electronic address:

Studies on the mechanism of clear cell renal cell carcinoma (ccRCC) progression are lacking. In this study, TOX3 was identified as a novel cancer suppressor gene in ccRCC. Hypermethylation of CpG probes in the promoter region was associated with the functional loss of TOX3 in ccRCC cancer tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.020DOI Listing
February 2019
1 Read

Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement.

Eur Urol Focus 2019 Feb 13. Epub 2019 Feb 13.

Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. Electronic address:

Background: Identification of clear and focused research priorities is crucial to drive research forward.

Objective: To identify research priorities in renal cell carcinoma (RCC) through a multidisciplinary collaboration between clinicians, researchers, and patients.

Design, Setting, And Participants: In phase I, 44 RCC experts provided 24 literature reviews within their field, summarising research gaps (RGs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.014DOI Listing
February 2019
1 Read

Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 17. Epub 2019 Jan 17.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Purpose: To investigate the impact of the risk group disagreement between the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models on prognosis.

Patients And Methods: We retrospectively evaluated 176 patients with metastatic renal-cell carcinoma who were treated with tyrosine kinase inhibitors as first-line therapy in 5 hospitals between October 2008 and August 2018. The risk group classification differences between the MSKCC and the IMDC models were evaluated using criteria of agreement (identical risk group in both the MSKCC and IMDC models) and disagreement (not identical risk group in both the MSKCC and IMDC models). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.006DOI Listing
January 2019
1 Read

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.

Eur J Cancer 2019 Feb 13;110:62-70. Epub 2019 Feb 13.

Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands. Electronic address:

Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)-positive in 67-96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18-64.7%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.035DOI Listing
February 2019
1 Read

Polymers with distinctive anticancer mechanism that kills MDR cancer cells and inhibits tumor metastasis.

Biomaterials 2019 Apr 25;199:76-87. Epub 2019 Jan 25.

Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669, Singapore. Electronic address:

Although mortality continues to decline over the past two decades, cancer is still a pervasive healthcare problem worldwide due to the increase in the number of cases, multidrug resistance (MDR) and metastasis. As a consequence of multidrug resistance, cancer treatment must rely on a host of chemotherapeutic agents and chemosensitizers to achieve remission. To overcome these problems, a series of biodegradable triblock copolymers of PEG, guanidinium-functionalized polycarbonate and polylactide (PEG-PGC-PDLA) is designed as chemotherapeutic agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2019.01.036DOI Listing
April 2019
1 Read

Viral genome integration of canine papillomavirus 16.

Papillomavirus Res 2019 Feb 13. Epub 2019 Feb 13.

Department of Pathology, Georgetown University Medical Center, Washington, DC, USA.

Papillomaviruses infect humans and animals, most often causing benign proliferations on skin or mucosal surfaces. Rarely, these infections persist and progress to cancer. In humans, this transformation most often occurs with high-risk papillomaviruses, where viral integration is a critical event in carcinogenesis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24058521183012
Publisher Site
http://dx.doi.org/10.1016/j.pvr.2019.02.002DOI Listing
February 2019
1 Read

Insight into Imiquimod Skin Permeation and Increased Delivery Using Microneedle Pre-treatment.

Eur J Pharm Biopharm 2019 Feb 13. Epub 2019 Feb 13.

Division of Advanced Materials and Healthcare Technologies, School of Pharmacy, The University of Nottingham, NG7 2RD, UK. Electronic address:

Basal cell carcinoma (BCC) is the most common skin cancer in humans. Topical treatment with imiquimod provides a non-invasive, self-administered treatment with relatively low treatment cost. Despite displaying excellent efficacy, imiquimod is only licensed by the FDA for superficial BCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2019.02.006DOI Listing
February 2019
1 Read

Anticancer and antimetastatic potential of enterolactone: clinical, preclinical and mechanistic perspectives.

Eur J Pharmacol 2019 Feb 13. Epub 2019 Feb 13.

Pharmaceutical Sciences, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra 411038, India.

Currently cancer is the second leading cause of death globally and worldwide incidence and mortality rates of all cancers of males and females are rising tremendously. In spite of advances in chemotherapy and radiation, metastasis and recurrence are considered as the major causes of cancer related deaths. Hence there is a mounting need to develop new therapeutic modalities to treat metastasis and recurrence in cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.02.022DOI Listing
February 2019
1 Read

Esophageal metastasis of breast cancer during endocrine therapy for pleural dissemination 21 years after breast surgery: a case report.

Surg Case Rep 2019 Feb 15;5(1):22. Epub 2019 Feb 15.

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa, Yokohama, Kanagawa, 236-0004, Japan.

Background: The esophageal metastasis of breast cancer is rare. Moreover, it is extremely unusual for patients to experience the symptoms of esophageal metastasis during their lifetimes. We present a case of dysphagia caused by esophageal metastasis after a long interval following a primary mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0585-xDOI Listing
February 2019
1 Read

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Cancer Immunol Immunother 2019 Feb 15. Epub 2019 Feb 15.

CureVac AG, Tübingen, Germany.

CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02315-xDOI Listing
February 2019
1 Read

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo.

Cancers (Basel) 2019 Feb 14;11(2). Epub 2019 Feb 14.

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK.

The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (NPs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020222DOI Listing
February 2019
1 Read

Folate-directed zinc (II) phthalocyanine loaded polymeric micelles engineered to generate reactive oxygen species for efficacious photodynamic therapy of cancers.

Photodiagnosis Photodyn Ther 2019 Feb 12. Epub 2019 Feb 12.

Department of Organic and Pharmaceutical Technology, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wroclaw, Poland. Electronic address:

Targeted and effective drug transport is becoming an attractive option in cancer therapy since it can improve drug efficacy and reduce drugs' side effects in normal tissues. In addition to using specific surface ligand molecules, the selective drug delivery can be accomplished via enhanced permeability and retention effect. Therefore, in our studies, we entrapped zinc (II) phthalocyanine (ZnPc) - a second generation photosensitizer - in folate-functionalized micelles of the biocompatible, FDA-approved for biomedical application diblock copolymer methoxypoly(ethylene oxide)-b-poly(L-lactide) (mPEG-b-PLLA) and its derivative with folate (FA) attached to the end of PEG chain (FA-PEG-b-PLLA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2019.02.014DOI Listing
February 2019
1 Read

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma.

Indian J Endocrinol Metab 2018 Nov-Dec;22(6):740-750

Department of Nuclear Medicine and Molecular Imaging, Amrita Institute of Medical Sciences, Amrita Vishwavidyapeetham, Cochin, Kerala, India.

Introduction: Differentiated thyroid carcinoma (DTC) is the most common pathological type of thyroid carcinoma, which includes papillary and follicular subtypes. DTC is usually indolent, characterized by good prognosis, and long-term survival. Total thyroidectomy is the mainstay of treatment in DTC which is followed by diagnostic whole body 131I (WBI) scan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijem.IJEM_70_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330860PMC
February 2019
2 Reads

[A Case of Breast Metastasis of Gastric Cancer after an Eight Year Latency Period].

Gan To Kagaku Ryoho 2019 Jan;46(1):154-156

Dept. of Surgery, Okayama Rosai Hospital.

A 66-year-old woman underwent distal gastrectomy because of gastric cancer(stage ⅠB)and received no adjuvant chemotherapy. Eight years after the operation, computed tomography showed a small nodule in the right breast. Mammography did not reveal any abnormalities. Read More

View Article

Download full-text PDF

Source
January 2019

[A Case of Gastric Neuroendocrine Carcinoma with Bulky Lymph Node Metastases, Solitary Liver Metastasis, and Left Adrenal Metastasis Curatively Resected after Chemotherapy].

Gan To Kagaku Ryoho 2019 Jan;46(1):103-105

Dept. of Surgery, Osaka City Juso Hospital.

A 68-year-old man presented with generalfatigue due to anemia. Gastrointestinalendoscopy showed a tumor approximately 60mm in diameter in the lesser curvature of the angle of the stomach. Large cell neuroendocrine carcinoma was diagnosed by biopsy of a tumor specimen. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

[Radiotherapy for Bone Metastasis after Esophageal Cancer Surgery].

Gan To Kagaku Ryoho 2019 Jan;46(1):91-93

Dept. of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences.

We examined the usefulness of radiotherapy for bone metastasis after esophageal cancer surgery. Between 2001 and 2016, we performed surgical resection for esophageal cancer in our department and 11 patients had postoperative bone metastases. Of these, 7 underwent radiotherapy. Read More

View Article

Download full-text PDF

Source
January 2019